Corcept Therapeutics Inc. | Mid-cap | Healthcare
$71.34
2.93%
| Corcept Therapeutics Stock Comparison:
Corcept Therapeutics vs VertexCorcept Therapeutics vs RegeneronCorcept Therapeutics vs Blueprint MedicinesCorcept Therapeutics vs Roivant SciencesCorcept Therapeutics vs Bio-TechneCorcept Therapeutics vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 675.0M
Gross Profit 664.2M 98.39%
Operating Income 137.0M 20.29%
Net Income 141.2M 20.92%
EPS (Diluted) $1.23

Balance Sheet Metrics

Total Assets 840.6M
Total Liabilities 161.0M
Shareholders Equity 679.6M
Debt to Equity 0.24

Cash Flow Metrics

Operating Cash Flow 163.0M
Free Cash Flow 195.9M

Revenue & Profitability Trend

Corcept Therapeutics Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 675.0M 482.4M 401.9M 366.0M 353.9M
Cost of Goods Sold 10.9M 6.5M 5.4M 5.3M 5.6M
Gross Profit 664.2M 475.9M 396.5M 360.7M 348.3M
Operating Expenses 527.2M 368.6M 283.8M 236.2M 220.1M
Operating Income 137.0M 107.3M 112.6M 124.5M 128.2M
Pre-tax Income 161.5M 124.6M 116.2M 125.0M 131.6M
Income Tax 20.3M 18.4M 14.8M 12.5M 25.6M
Net Income 141.2M 106.1M 101.4M 112.5M 106.0M
EPS (Diluted) $1.23 $0.94 $0.87 $0.89 $0.85

Income Statement Trend

Corcept Therapeutics Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 471.6M 458.6M 499.3M 266.5M 478.5M
Non-Current Assets 369.0M 162.9M 84.2M 157.3M 93.2M
Total Assets 840.6M 621.5M 583.4M 423.8M 571.7M
Liabilities
Current Liabilities 140.8M 104.5M 72.5M 47.5M 47.5M
Non-Current Liabilities 20.2M 10.3M 9.1M 409.0K 899.0K
Total Liabilities 161.0M 114.8M 81.6M 48.0M 48.4M
Equity
Total Shareholders Equity 679.6M 506.7M 501.8M 375.8M 523.3M

Balance Sheet Composition

Corcept Therapeutics Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income 141.2M 106.1M 101.4M 112.5M 106.0M
Operating Cash Flow 163.0M 122.2M 99.1M 161.6M 145.9M
Investing Activities
Capital Expenditures -2.2M -139.0K -413.0K -469.0K -1.2M
Investing Cash Flow -177.6M 90.9M -114.3M 136.1M -119.3M
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow -22.3M -154.5M -21.7M -318.8M -11.0M
Free Cash Flow 195.9M 126.9M 119.9M 167.4M 150.7M

Cash Flow Trend

Corcept Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 62.07
Forward P/E 40.79
Price to Book 11.07
Price to Sales 11.04
PEG Ratio 40.79

Profitability Ratios

Profit Margin 19.55%
Operating Margin 2.17%
Return on Equity 21.77%
Return on Assets 9.18%

Financial Health

Current Ratio 3.06
Debt to Equity 1.00
Beta 0.18

Per Share Data

EPS (TTM) $1.15
Book Value per Share $6.45
Revenue per Share $6.62

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
cort 7.6B 62.07 11.07 21.77% 19.55% 1.00
Vertex 114.1B 32.82 6.92 -5.64% -8.91% 10.00
Regeneron 55.3B 13.02 1.84 15.96% 31.94% 9.20
Blueprint Medicines 8.3B -120.00 24.19 -47.71% -27.70% 208.50
Roivant Sciences 7.8B 1.95 1.71 -12.54% 96.86% 1.93
Bio-Techne 7.9B 60.87 3.92 6.53% 10.89% 20.99

Financial data is updated regularly. All figures are in the company's reporting currency.